Assessment of drug-drug interactions of CC-90001, a potent and selective inhibitor of c-Jun N-terminal kinase
Author:
Affiliation:
1. Nonclinical Development, Bristol Myers Squibb, Summit, NJ, USA
2. Clinical Pharmacology, Bristol Myers Squibb, Summit, NJ, USA
Funder
Bristol Myers Squibb
Publisher
Informa UK Limited
Subject
Health, Toxicology and Mutagenesis,Pharmacology,Toxicology,Biochemistry,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/00498254.2022.2027553
Reference33 articles.
1. c-Jun N-Terminal Kinase 1 Is Required for the Development of Pulmonary Fibrosis
2. Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method
3. In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine
4. Assessment of Transporter‐Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Phase 2, Double-Blind, Placebo-controlled Trial of a c-Jun N-Terminal Kinase Inhibitor in Idiopathic Pulmonary Fibrosis;American Journal of Respiratory and Critical Care Medicine;2024-08-15
2. Safety, Pharmacokinetics, and Antifibrotic Activity of CC‐90001 (BMS‐986360), a c‐Jun N‐Terminal Kinase Inhibitor, in Pulmonary Fibrosis;Clinical Pharmacology in Drug Development;2023-06-28
3. Non-kinase targeting of oncogenic c-Jun N-terminal kinase (JNK) signaling: the future of clinically viable cancer treatments;Biochemical Society Transactions;2022-12-01
4. Safety, Pharmacokinetics, and Pharmacodynamics of CC‐90001 (BMS‐986360), a c‐Jun N‐terminal Kinase Inhibitor, in Phase 1 Studies in Healthy Participants;Clinical Pharmacology in Drug Development;2022-10-18
5. Polymorphisms of pharmacogenetic candidate genes affect etomidate anesthesia susceptibility;Frontiers in Genetics;2022-09-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3